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Aim To investigate whether the sex-dependent expres-
sion of hepatic and renal oxalate transporter sat-1 (Slc26a1) 
changes in a rat model of ethylene glycol (EG)-induced hy-
peroxaluria.
Methods Rats were given tap water (12 males and 12 fe-
males; controls) or EG (12 males and 12 females; 0.75% 
v/v in tap water) for one month. Oxaluric state was con-
firmed by biochemical parameters in blood plasma, urine, 
and tissues. Expression of sat-1 and rate-limiting enzymes 
of oxalate synthesis, alcohol dehydrogenase 1 (Adh1) and 
hydroxy-acid oxidase 1 (Hao1), was determined by immu-
nocytochemistry (protein) and/or real time reverse tran-
scription polymerase chain reaction (mRNA).
Results EG-treated males had significantly higher (in 
μmol/L; mean ± standard deviation) plasma (59.7 ± 27.2 vs 
12.9 ± 4.1, P < 0.001) and urine (3716 ± 1726 vs 241 ± 204, 
P < 0.001) oxalate levels, and more abundant oxalate 
crystaluria than controls, while the liver and kidney sat-1 
protein and mRNA expression did not differ significantly 
between these groups. EG-treated females, in compari-
son with controls had significantly higher (in μmol/L) se-
rum oxalate levels (18.8 ± 2.9 vs 11.6 ± 4.9, P < 0.001), un-
changed urine oxalate levels, low oxalate crystaluria, and 
significantly higher expression (in relative fluorescence 
units) of the liver (1.59 ± 0.61 vs 0.56 ± 0.39, P = 0.006) and 
kidney (1.77 ± 0.42 vs 0.69 ± 0.27, P < 0.001) sat-1 protein, 
but not mRNA. The mRNA expression of Adh1 was female-
dominant and that of Hao1 male-dominant, but both were 
unaffected by EG treatment.
Conclusions An increased expression of hepatic and renal 
oxalate transporting protein sat-1 in EG-treated female rats 
could protect from hyperoxaluria and oxalate urolithiasis.
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Hyperoxaluria is one of the main causes of stone forma-
tion in the urinary tract, and results in urine oversaturation 
with calcium oxalate. It can be induced by an excess of di-
etary oxalate intake or develop secondary to wide range of 
disorders (1-3). Urinary oxalate excretion and incidence of 
urolithiasis in humans and rodents are sex-related, occur-
ring 2-3-times more often in males, but the reasons for this 
are not quite clear (4-12).
Exogenous oxalate is absorbed from food by paracellular 
diffusion and transcellularly by secondary-active trans-
porters of the SLC26 family (13,14). Endogenous oxalate 
is mainly produced in hepatocytes (15-17) and extruded 
across the sinusoidal membrane in exchange for sulfate 
by the sulfate anion transporter sat-1 (Slc26a1) (18,19). 
It is eliminated from the body partially by secretion into 
the intestine and largely by excretion in the kidneys 
(3,20). In renal proximal tubules, oxalate is freely filtered, 
partially reabsorbed, and additionally secreted into the 
tubule fluid, resulting in a fractional excretion of 120%-
130% (21). Renal secretion of oxalate includes sat-1-me-
diated uptake across the basolateral membrane (BLM) 
and release across the brush-border membrane (BBM) 
into the tubule fluid by the chloride-formate exchang-
er CFEX (Slc26a6) and/or the diastrophic dysplasia sul-
fate transporter DTDST (Slc26a2) (3,18,19,22). Mice lack-
ing sat-1 or CFEX develop hyperoxalemia, hyperoxaluria, 
calcium-oxalate nephrocalcinosis, and tubular damage 
(9,23,24).
The role of sat-1 in development of sex-related urolithia-
sis has not been well investigated in in vivo animal mod-
els. In rats, hepatic and renal sat-1 expression was higher 
in males than in females (19), which may contribute to a 
higher prevalence of urolithiasis in males. Also, in male rats, 
increased hepatic and renal sat-1 expression were not as-
sociated with hyperoxaluria (25), while in female rats this 
issue has not been investigated.
Here we used the existing rat model of experimental 
hyperoxaluria, in which female and male animals are 
treated with an oxalate precursor, ethylene glycol (EG) 
(26-28) in order to test if this pathophysiological condi-
tion changes protein expression of hepatic and renal ox-
alate transporter sat-1 (Slc26a1). In these organs of both 
sexes, we analyzed the mRNA and protein expression 
of sat-1, and mRNA expression of the two rate-limiting 
enzymes of EG metabolism, alcohol dehydrogenase 1 




We used 24 male and 24 female three-month old Wistar 
rats from the breeding colony at the Institute for Medical 
Research and Occupational Health in Zagreb. The experi-
ments were conducted during 2012 and 2013. Animal care 
conformed to the institutional regulations, which com-
ply with international guidelines (29). Experiments were 
approved by the Institutional Ethics Committee. Animals 
were provided with standard pelleted food (Mucedola, 
Settimo Milanese, Italy) and either tap water (controls; 12 
female and 12 male animals) or EG in tap water (0.75%, vol/
vol; changed daily; EG-treated 12 female and 12 male ani-
mals) for one month.
Sampling of urine, blood, and organs
Two days before sacrifice, rats were placed in individual 
metabolic cages with free access to water (control animals) 
or EG solution (EG-treated animals), but without food. Urine 
was collected for 24 hours. Body mass and the volume of 
each animal’s urine was measured. Urine was centrifuged 
at 2500 g for 15 min. In the supernatant, biochemical pa-
rameters were determined. The pellet was resuspended in 
1 mL of the supernatant for testing the presence of oxalate 
crystals by light microscopy under phase contrast.
On the 31st day after the start of EG-treatment, rats were 
anaesthetized (Narketan, 80 mg/kg b.m and Xylapan, 12 
mg/kg b.m., i.p.), 4-5 mL blood was collected from the 
heart by percutaneous puncture using heparinized va-
cutainer, and centrifuged (2500 g for 10 min) to obtain 
plasma. The animals were bled out, and the liver and kid-
neys were sampled. These procedures were performed be-
tween 8 and 12 am.
Determination of biochemical parameters
Plasma urea levels and urine creatinine and calcium lev-
els were measured in native samples with the automated 
analyzer Cobas c501 (Roche, Hellerup, Germany). Aliquots 
of blood plasma were filtered through Ultra-free-MC Mil-
lipore filters (10 kDa cut-off ) by centrifugation at 2000 g 
for 30 min to remove proteins. Ultrafiltrate and aliquots 
of urine were acidified by 1 N HCl, and oxalate and cit-
rate levels were measured by ion chromatography with a 
conductivity detector (Dionex, Sunyvale, CA, USA) (30,31). 
The lipid peroxidation product malondialdehyde (MDA) in 
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blood plasma, urine, and liver and kidney tissue homoge-
nates was measured by high pressure liquid chromatog-
raphy (HPLC) (32-34), whereas reduced glutathione (GSH) 
in blood plasma and liver and kidney tissue homogenates 
was analyzed spectrophotometrically (35). Chemical ele-
ments in urine samples (Ca, Mg, P, Na, K, S, I, Sr, Se, Fe, Cu, 
Zn, Co, B, As, Ba, and Li) were analyzed using the inductive-
ly-coupled plasma mass spectrometry (IC-PMS) (36). Urine 
protein concentration was measured by the Bradford as-
say (37). MDA and GSH were obtained from 6, and all oth-
er biochemical parameters from 10-12 animals from each 
group.
Antibodies, chemicals, and other material
Monoclonal antibodies for rat sat-1 (sat-1-Ab) and α-actin 
(actin-Ab), and polyclonal antibody for cell adhesion mol-
ecule 105 (CAM105-Ab) were used as previously described 
(18,19,22,38). CY3-labeled secondary antibodies (donkey 
anti-mouse [DAMCY3] and goat anti-rabbit [GARCY3] IgG) 
were purchased from Jackson ImmunoResearch (West 
Grove, PA, USA). Narketan and Xylapan were purchased 
from Chassot (Bern, Switzerland) and EG from Merck (Darm-
stadt, Germany). Other chemicals were of the highest avail-
able purity and purchased from either Sigma-Aldrich (St. 
Louis, MO, USA) or Fisher Scientific (Pittsburgh, PA, USA).
tissue fixation, immunocytochemistry, and 
determination of fluorescence pixel intensity
Tissue fixation with 4% p-formaldehyde in animals in vivo, 
cryosectioning, optimal antigen retrieval, and immunos-
taining protocols for sat-1, actin, and CAM105, and fluo-
rescence microscopy were performed as previously de-
scribed (19,38,39). Immunostaining was analyzed with 
Opton III RS fluorescence microscope (Opton Feintechnik, 
Oberkochen, Germany). The images were taken with digi-
tal Spot RT slider camera and software (Diagnostic Instru-
ments, Sterling Heights, MI, USA), and processed in Adobe 
Photoshop 6.0 (Adobe Systems Inc., San Jose, CA, USA). The 
software settings were adjusted to the strongest fluores-
cence intensity in a set of cryosections, and all the images 
were taken using the same settings.
The intensity of CY3 fluorescence (pixel intensity) was 
measured in the original images using the Image-J soft-
ware, version 1.4 (NIH, Bethesda, MD, USA). Our previous 
studies on sat-1-Ab and other antibodies showed a good 
correlation between the abundance of protein in isolated 
membranes, represented by the protein band density in 
Western blots, and fluorescence pixel intensity in immuno-
cytochemical images (19,40,41). Accordingly, in this study 
only pixel intensity was determined.
A single tissue cryosection was taken from each liver (6 ani-
mals per group) and immunostained for sat-1 or CAM105. 
Three images of each cryosection were taken using a 
40 × objective. In each image, 10-15 randomly chosen 
staining-positive regions of interest (ROI) (sat-1-positive si-
nusoidal membrane or CAM105-positive canalicular mem-
brane) were circled, fluorescence pixel intensity was mea-
sured, averaged, and corrected for the background pixel 
intensity of unstained cytoplasm. Also from 6 animals per 
group, one kidney tissue cryosection was taken and im-
munostained with sat-1-Ab or CAM105-Ab. Three images 
of each cryosection in the cortex and outer stripe were tak-
en with a 25 × objective. In each image, 5-8 representative 
ROIs were circled (sat-1-positive BLM in the cortical convo-
luted tubules or CAM105-positive BBM in the inner stripe 
tubules), fluorescence pixel intensity was measured, aver-
aged, and corrected for the background staining intensity 
measured in the unstained cell cytoplasm. The final data 
were expressed relative to the strongest fluorescence pixel 
intensity measured in images from the respective control 
animal.
RNA isolation, complementary DNA (cDNA) synthesis, 
and quantitative real-time reverse transcription 
polymerase chain reaction (qRt-PCR)
After sacrifice, a slice of liver was promptly immersed into 
RNAlater solution (Sigma). Kidneys were decapsulated and 
a ~ 1-mm thick middle slice was immediately submerged 
into the RNAlater solution (Sigma). Total cellular RNA from 
corresponding tissues ( ~ 50 mg of each organ) was extract-
ed using Trizol (Invitrogen, Karlsruhe, Germany), according 
to the manufacturer’s instructions. RNA concentration and 
its purity were estimated by the spectrophotometric mea-
surement of optical density at 260 and 280 nm (BioSpec 
Nano, Shimadzu, Kyoto, Japan). The integrity of RNA was 
verified by agarose gel electrophoresis. Isolated RNA was 
stored at -70°C until further use.
First strand cDNA synthesis was performed by High-Capac-
ity cDNA Reverse Transcription Kits (Applied Biosystems, 
Foster City, CA, USA) in accordance with the manufactur-
er’s instructions. Synthesized cDNA was stored at -20°C 
until use. qRT-PCR was performed in a 50 µL volume us-
ing 50 ng of the first strand cDNA template, 2.5 µL of 
20 × TaqMan Gene Expression Assays mix, 25 µL of 
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2 × TaqMan Universal PCR Master Mix (all from Applied Bio-
systems), and 17.5 µL of nuclease-free water. Primers and 
probes were designed by Applied Biosystems and sup-
plied as TaqMan Gene Expression Assays mix containing 
a 20 × mix of unlabeled PCR forward and reverse primers, 
as well as TaqMan MGB probe. Assay IDs for the rat genes 
were Rn01637788_m1 (sat-1), Rn00570670_m1 (Adh1), 
Rn01486035_m1 (Hao1) and Rn00667869_m1 (β-actin). 
Amplification and detection were performed using the 
7500 RT-PCR System (Applied Biosystems). Thermal cycling 
conditions were 2 min at 50°C and 10 min at 95°C, followed 
by 40 two-step cycles of denaturation (15 sec at 95°C) and 
annealing/extension (1 min at 60°C). mRNA quantification 
was performed using TaqMan Assays from Applied Biosys-
tems (available from http://www.appliedbiosystems.com) 
according to manufacturer’s instructions. Nontemplate 
control reactions, where cDNA was substituted with nu-
clease-free water, were included in each run to check for 
possible contamination. To standardize the input of cDNA 
amount, an endogenous control, ie, the house-keeping 
gene, β-actin was quantified and results were normalized 
to these values. Each reaction was performed in duplicate. 
tABLe 1. Body mass, urine excretion, and relevant biochemical parameters in blood plasma and urine of control and ethylene glycol 











Body mass (g) 196 ± 17.3 198 ± 10.4 340 ± 20.8†  351 ± 24.2
Parameters in blood plasma
Citrate (ultrafiltrate) (µmol/L) 153 ± 48.5 143 ± 31.2 136 ± 38.1   77 ± 38.1‡
Oxalate (ultrafiltrate) (µmol/L)  11.6 ± 4.9  18.8 ± 2.9†  12.9 ± 4.1   59.7 ± 27.2‡
Creatinine (mmol/L)  29 ± 14.5  33 ± 14.9  38 ± 6.6   43 ± 9.4
Urea (μmol/L)   7.7 ± 2.94   6.4 ± 1.21   6.1 ± 0.48    6.6 ± 0.94
Parameters in urine
Volume (mL/24 h)  17.3 ± 9.6  24.0 ± 9.5  31.2 ± 12.9§   30.6 ± 7.9
Flow (mL/24 h kg b. m.*)  99 ± 55.4 121 ± 48.5  92 ± 34.6   95 ± 31.2
Protein (mg/24 h kg b.m.)  21 ± 8.6  18 ± 7.5  35 ± 16.1§   30 ± 21.2
Calcium
μmol/L   3.7 ± 1.59   2.5 ± 1.87   1.1 ± 0.97†    0.09 ± 0.03ǁ
nmol/24 h kg b.m. 283 ± 113.6 258 ± 186.7  79 ± 54.7†    9.3 ± 7.59‡
Citrate  
mmol/L   5.5 ± 2.67   4.4 ± 3.12   3.6 ± 3.74    2.2 ± 0.97
μmol/24 h kg b.m. 409 ± 197.4 435 ± 325.6 229 ± 100.5¶  200 ± 114.3
Creatinine
mmol/L   5.3 ± 2.91   3.7 ± 1.45   4.4 ± 3.43    3.8 ± 1.32
μmol/24 h kg b.m. 360 ± 69.3 371 ± 58.9 302 ± 83.1  334 ± 90.1
oxalate
µmol/L 161 ± 90.1 161 ± 83.1 241 ± 204.4 3716 ± 1826‡
µmol/24 h kg b.m.  12.5 ± 6.1  20.8 ± 20.0  17.0 ± 7.1  322 ± 135.1‡
mmol/mol creatinine  34 ± 13.2  55 ± 54.0  61 ± 28.1§  994 ± 391.4‡
Magnesium
mmol/L   8.4 ± 3.45   7.1 ± 2.21   2.7 ± 2.12†    5.0 ± 3.07
mmol/24 h kg b.m.   0.71 ± 0.16   0.78 ± 0.16   0.24 ± 0.15†    0.46 ± 0.22**
Phosphate
mmol/L  26 ± 12.8  22 ± 6.3  14 ± 6.9¶   16 ± 7.7
mmol/24 h kg b.m.   2.2 ± 0.41   2.4 ± 0.57   1.1 ± 0.41†    1.4 ± 0.38
*Body mass (b.m.).
†P < 0.001 vs control females.
‡P < 0.001 vs control males.
§P = 0.007 vs control females.
ǁP = 0.002 vs control males.
¶P = 0.011-0.016) vs control females.
**P = 0.018 vs control males. other comparisons were not statistically significant (P > 0.05).
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Quantification of mRNA expression was accomplished by 
comparative Ct-method using the Relative Quantification 
Study Software (Applied Biosystems) (42). qRT-PCR study 
was performed with cDNA obtained from 5 (liver) and 6 
(kidneys) independent RNA preparations from control and 
EG-treated rats of both sexes.
Statistical analysis
Data are expressed as mean ± standard deviation (SD). The 
differences between groups were tested with t test using 
STATISTICA software (StatSoft Version 12, Tulsa, OK, USA). 
The level of statistical significance was set at P < 0.05.
ReSuLtS
effect of eG treatment: biochemical parameters, oxalate 
crystaluria, and tissue morphology in control and eG-
treated female and male animals
Control males had significantly higher body mass, urine 
volume, urinary protein excretion rate, and urine oxalate 
relative to creatinine, and significantly lower urine calci-
um, citrate, magnesium, and phosphate than control fe-
males (Table 1). There were no differences between sexes 
in plasma and urinary creatinine and plasma urea. In com-
parison with control females, EG-treated females had ~ 60% 
higher (P < 0.001) plasma oxalate; there were no differenc-
es in any other plasma parameter. Notably, EG treatment 
did not increase urinary oxalate excretion. EG-treated males 
had significantly lower plasma citrate (P < 0.001), urine cal-
cium concentration (P = 0.002), and calcium excretion rate 
(P < 0.001), significantly higher magnesium excretion rate 
(P = 0.018), and higher plasma oxalate ( ~ 4.6-fold; P < 0.001), 
urine oxalate concentration ( ~ 15-fold; P < 0.001), and ox-
alate excretion rate ( ~ 18-fold; P < 0.001) than control males. 
Other elements determined in urine (Na, K, S, I, Sr, Se, Fe, 
Cu, Zn, Co, B, As, Ba, and Li) were excreted with a significant 
variability, exhibiting no major differences between experi-
mental groups of animals (data not shown). MDA and GSH 
levels showed inconsistent results, suggesting no differenc-
es among groups in oxidative status (data not shown).
Control and EG-treated female rats had low abundance of 
small-sized oxalate crystals in urine sediment (Figures 1A 
and B). Control males had numerous crystals of hetero-
FIGuRe 1. oxalate crystals in urine sediments of control (ctrl) 
(A) and ethylene glycol (eG)-treated (eg) (B) female, and in 
control (C) and eG-treated (D) male rats. Prism- and rod-like 
crystals of various sizes were observed in all samples (arrows), 
while numerous large crystals were observed in 7 out of 12 eG-
treated males (D) (asterisks). In 5 eG-treated males, crystaluria 
was similar to control males. Accumulation of the dust-like 
crystals was occasionally observed in the sediments from 
control (not shown) and eG-treated (B) animals (arrowheads). 
Bar, 50 μm.
FIGuRe 2. tissue morphology of the kidney cortex in control 
(ctrl) and ethylene glycol (eG)-treated (eg) female and male 
rats in tissue cryosections immunostained with actin-Ab. In 
the kidneys of control animals of both sexes, we observed 
regular dense arrangements of undamaged glomeruli (G), 
closed proximal convoluted tubules with thick epithelium and 
brightly-stained brush-border (arrowheads), and distal tubules 
and collecting ducts with narrow or closed lumen (arrows). 
In the kidney cortex of the eG-treated animals of both sexes, 
distal tubules and collecting ducts had thin epithelium and 
distended lumen (arrows). In the eG-treated males, many 
proximal convoluted tubules had wide lumen, thin epitheli-
um, and variable loss of brush border (arrowheads). Images 
represent findings in 10 animals from each experimental 
group. Bar, 50 μm.
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geneous size (Figure 1C), whereas 7 out of 12 EG-treated 
males (60%) had a myriad of crystals, very heterogeneous 
in size (Figure 1D). Five EG-treated males (40%) had similar 
number and size of oxalate crystals as controls, in spite of 
strongly elevated plasma and urine oxalate levels.
Tissue morphology in control and EG-treated rats was test-
ed in cryosections immunostained with actin-Ab. The liv-
er tissue of all animals (not shown) and kidney cortex of 
control females and males (Figure 2) showed regular actin 
staining and undamaged tissue morphology. In EG-treated 
females, the overall actin staining was not visibly changed, 
but many distal tubules and collecting ducts had distend-
ed lumina and flattened epithelia. In EG-treated males (Fig-
ure 2), most distal tubules and collecting ducts also had 
distended lumina and flattened epithelium, and some rats 
had visible loss of actin and damaged proximal tubules.
expression of sat-1 protein and mRNA
Sat-1-Ab-related staining intensity of the hepatocyte si-
nusoidal membrane in control rats was male-dominant, 
FIGuRe 3. Sulfate anion transporter sat-1 (Slc26a1) and cell adhesion molecule 105 (CAM105) protein expression (A, B, D, E) and 
sat-1 mRNA expresion (C, F) in the liver of control (ctrl) and eG-treated (eg) rats. (A-C) Data in female rats. (A) Immunostaining in tis-
sue cryosections. In eG-treated females the intensity of sat-1-related staining of the hepatocyte sinusoidal membrane was stronger, 
whereas the intensity of CAM105-related staining, localized to both sinusoidal and canalicular membranes, was similar to that in 
control females. (B) Relative fluorescence pixel intensity showed ~ 3-fold increase in the sat-1-related staining intensity in eG-treated 
females (*vs control, P < 0.001; n = 6 in each group) and no significant change for CAM105 (vs control, P = 0.828; n = 6 in each group). 
(C) Relative expression of sat-1 mRNA was similar in control and eG-treated female rats (P = 0.939; n = 5 in each group). (D-F) Data 
in male rats. (D) Immunostaining in tissue cryosections. In eG-treated males the intensity of sat-1-related staining of the sinusoidal 
membrane was similar to that in control males, and the same is valid for CAM105. (E) Relative fluorescence pixel intensity showed 
similar staining intensity (P > 0.05) in control and eG-treated males for both sat-1 (P = 0.496) and CAM105 (P = 0.5175) (n = 6 in each 
group). (F) Relative expression of sat-1 mRNA was similar in control and eG-treated males (P = 0.513; n = 5 in each group). CV, 
central vein. Bars, 20 μm.
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which is in accordance with our previous findings (19) 
(Figures 3A and 3D). In control females (Figure 3A), sat-1
-Ab weakly stained hepatocytes around the central vein; 
the staining diminished toward the lobule periphery. In 
EG-treated females, similar staining pattern was observed, 
but with ~ 3-fold higher fluorescence intensity (Figures 3A 
and 3B). The expression of sat-1 mRNA was similar in the 
liver tissue of control and EG-treated females (Figure 3C). 
The pattern of CAM105-Ab-related staining intensity in the 
canalicular (strong) and sinusoidal (weak) membranes in 
females was not affected by EG (Figures 3A and 3B). Con-
trol and EG-treated males had similar staining intensity of 
both sat-1 and CAM105 (Figures 3D and 3E), as well as the 
expression of sat-1 mRNA (Figure 3F).
Sat-1-Ab-related staining intensity in the basolateral mem-
brane of cortical proximal tubule cells in control animals 
was male-dominant, which is in accordance with our previ-
ous findings (19) (Figures 4A and 4D). In EG-treated females, 
the staining intensity of sat-1 increased ~ 3-fold, whereas the 
CAM105-related staining remained unchanged in both sex-
es (Figures 4A and 4B, and Figures 4D and 4E, respectively). 
FIGuRe 4. Sulfate anion transporter sat-1 (Slc26a1) and cell adhesion molecule 105 (CAM105) protein expression (A, B, D, E) and sat-1 
mRNA expression (C, F) in the kidneys of control (ctrl) and eG-treated (eg) rats. (A-C) Data in female rats. (A) Immunostaining in tissue 
cryosections. In eG-treated females the intensity of sat-1-related staining of the basolateral membrane in cortical proximal tubules 
was stronger than that in controls, whereas the intensity of CAM105-related staining, localized to the proximal tubule brush-border 
membrane, was similar. (B) Relative fluorescence pixel intensity showed ~ 3-fold increase in the sat-1-related staining intensity in 
eG-treated females (*vs control, P < 0.001; n = 6 in each group) and no change for CAM105 (P = 0.731; n = 6 in each group). (C) Relative 
expression of sat-1 mRNA was similar in control and eG-treated female rats (P = 0.223; n = 6 in each group). (D-F) Data in male rats. 
(D) Immunostaining in tissue cryosections. In eG-treated males the intensity of sat-1-related staining of the basolateral membrane 
in cortical proximal tubules, and the CAM105-related staining in the proximal tubule brush-border membrane, was similar to that 
in controls. (E) Relative fluorescence pixel intensity showed no differences in the sat-1-related (P = 0.927) and CAM105-related 
(P = 0.220) staining intensity between the control and eG-treated males (n = 6 in each group). (F) Relative expression of sat-1 
mRNA was similar in control and eG-treated male rats (P = 0.125; n = 6 in each group). Bar, 20 μm.
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The expression of sat-1 mRNA in the kidneys was not affect-
ed by EG-treatment in either sex (Figures 4C and 4F).
mRNA expression of the rate-limiting enzymes in eG 
metabolism
To estimate if the capacity to produce oxalate in the liver 
and kidneys was affected by EG-treatment in female and 
male rats, we determined by qRT-PCR the mRNA expres-
sion of two major rate limiting enzymes of EG metabo-
lism, Adh1 and Hao1. Adh1 oxidizes EG to glycoaldehyde, 
whereas Hao1 catalyzes conversion of glycolic acid to gly-
oxylic acid (Figure 5).
In the liver and kidneys of control animals, the relative ex-
pression of Adh1 mRNA in females was respectively ~ 2-fold 
and ~ 4.5-fold higher than in males, and remained unaffect-
ed by EG-treatment in both sexes (Figure 6A). The relative 
expression of Hao1 mRNA in the liver and kidneys in con-
trol males was respectively ~ 2.5-fold and ~ 4-fold higher 
than in females and was also unaffected by EG-treatment 
in both sexes (Figure 6B).
DISCuSSIoN
Our study showed hyperoxalemia and hyperoxaluria in 
EG-treated male rats but surprisingly not in female rats. 
Non-significant differences in plasma creatinine and urea 
confirmed an absence of uremia in EG-treated animals. 
Furthermore, EG-unaffected liver morphology in both sex-
es indicated that even strong oxalemia, which occurred in 
EG-treated males, did not change the cell integrity of he-
patocytes. However, the kidneys of EG-treated animals ex-
hibited limited morphological damage in several nephron 
segments and a variable loss of actin. These observations 
match previous findings (6,12,43-45), which in some stud-
ies were attributed to EG-induced oxidative stress (43,46). 
However, in our study MDA and GSH data indicated no sig-
nificant oxidative stress in animals.
In control rats, plasma oxalate was similar in both sex-
es, ~ 12 μmol/L, which corresponds to the values previ-
ously published for rodents (7-24 μmol/L) (24,25,27,47,48). 
In control females, urine oxalate concentration and excre-
tion rate was low, as was the abundance of typical prism- 
and rod-like oxalate crystals. Oxalate stone formation may 
have been prevented by higher urine citrate concentra-
tion, which complexed calcium ions. In addition, the high-
er magnesium concentrations may have displaced calci-
um as binding partner for oxalate (49-53). Control males 
showed a tendency to have higher urine oxalate concen-
tration and a significantly higher excretion rate than con-
trol females. In males, lower urine citrate and magnesium 
suggest more favorable conditions for crystallization, re-
sulting in an abundance of larger oxalate crystals.
Sex differences in mRNA expression of the rate-limiting en-
zymes of EG metabolism are in agreement with previous 
observations in rat liver and kidneys; the female-dominant 
Adh1 activity and mRNA expression in the liver and kid-
neys was driven by estrogens (54-57), whereas the male-
dominant Hao1 activity and mRNA expression in both or-
gans resulted from androgen stimulation and estrogen 
inhibition (43,58,59).
EG-treated rats exhibited oxalemia and oxaluria, which is 
in accordance with previous studies (25,27,28). EG-treated 
FIGuRe 5. enzymes that catalyze major steps in metabolic 
conversion of ethylene glycol (eG) to the end product oxalate 
in the liver. the first step, conversion of eG to glycoaldehyde, 
is catalyzed by cytosolic alcohol dehydrogenases 1 (Adh1; eC 
1.1.1.1). Glycoaldehyde is metabolized by aldehyde dehy-
drogenase (eC 1.2.1.3) to glycolate (glycolic acid), which is 
subsequently metabolized to glyoxylate (glyoxylic acid) 
by hydroxy-acid oxidase 1 (Hao1; eC 1.1.3.15), and then 
converted by lactate dehydrogenase (eC 1.1.1.27) to oxalate 
(oxalic acid). Modified from Williams and Wilson (64) and 
Hagler and Herman (65).
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males exhibited low plasma citrate, strong oxalemia ( ~ 4.6-
fold above controls), very low urine calcium, hyperoxaluria 
( ~ 18-fold above controls), and increased excretion rate of 
magnesium. The abundance and size of oxalate crystals in-
creased dramatically in most, but not all, EG-treated males 
although all of them had hyperoxaluria (15-20-fold above 
controls). Unexpectedly, EG-treated females showed rela-
tively weak oxalemia ( ~ 60% above controls), with other 
plasma and urine parameters unchanged. They had similar 
urine oxalate level and the abundance and size of urine ox-
alate crystals as control females.
It is well-known that testosterone enhances and estrogen 
inhibits the EG-induced urinary stone formation in rats (6,7), 
but the pathophysiological processes underlying these dif-
ferences are unclear. All EG-treated animals drunk the same 
EG-containing water for one month, but weak oxalemia 
and absence of oxaluria in females indicates either a much 
weaker production of oxalate or a much faster elimination 
of oxalate by some non-renal mechanism, or both.
Regarding oxalate production, we speculate that a) EG 
should readily cross biological membranes by nonionic 
diffusion, rendering sex differences in intestinal absorp-
tion and availability for metabolism in the liver unlikely; b) 
females did not ingest less EG-containing water because 
urine flow in all animal groups was similar, which indicates 
similar relative uptake and loss of water; c) the relative ex-
pression of major EG-metabolizing enzymes, Adh1 and 
Hao1 mRNA in the liver and kidneys was unaffected by 
EG treatment in both sexes. In accordance with our mRNA 
findings, Hao1 activity in the liver of male rats was previ-
ously found to be unaffected by EG-treatment (58). Future 
studies need to clarify whether the low expression of Hao1 
in female rats was possibly a limiting factor in oxalate pro-
duction from EG, resulting in the observed modest hyper-
oxalemia in these animals.
Recent studies in knockout mice revealed that several 
anion exchangers from the Slc26 family, including sat-1 
and CFEX, together controlled oxalate pathways in 
FIGuRe 6. Relative expression of Adh1 (A) and Hao1 mRNA (B) in the liver and kidneys of control (Ctr) and ethylene glycol (eG)-
treated (eG) female and male rats. (A) In the liver and kidneys of control animals, the relative expression of Adh1 mRNA in females 
was respectively ~ 2-fold (*P = 0.028) and ~ 4.3-fold (*P < 0.001) higher than in males, and remained unaffected by eG-treatment in 
both sexes (vs the respective control data, P ≥ 0.127). (B) In the liver and kidneys of control animals, the relative expression of Hao1 
mRNA in males was respectively ~ 3-fold (*P < 0.001) and ~ 4-fold (*P < 0.001) higher than in females, and remained unaffected by eG-
treatment in both sexes (vs the respective control data, P≥0.167). Bars represent the data from 5 (liver) and 6 (kidney) animals.
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the intestine (absorption and secretion), liver (production 
and extrusion), and kidneys (partial reabsorption and se-
cretion). Knockout of sat-1 and CFEX induced oxalemia, 
hyperoxaluria, and oxalate nephrolithiasis (3,9,20,23,24). 
These studies concluded that under physiological con-
ditions sat-1 and CFEX contributed to oxalate secretion 
in the kidneys and intestine, thus protecting from signif-
icant oxalemia and oxaluria. In sat-1- and CFEX-deficient 
mice, the secretory components were diminished, while 
the absorptive processes in the small intestine prevailed. 
The enhanced absorption of dietary oxalate causes hy-
peroxalemia, massive oxalate filtration, hyperoxaluria, and 
nephrolithiasis (3,20). Thus, these studies identified oxalate 
transporters from the Slc26 family in the rodent intestine 
as major contributors to handling of plasma and urine ox-
alate. However, later studies showed that a) hyperoxalu-
ria in male rats did not alter the renal expression of sat-1 
mRNA or protein abundance (25), which is in accordance 
with our data in EG-treated male rats, and b) sat-1 was not 
important for oxalate secretion across the mouse duode-
num, but its role in oxalate secretion may be confined to 
more distal parts of the intestine (60).
Our previous study (19) showed mRNA-independent, 
male-dominant expression of sat-1 protein in the rat liver 
and kidneys due to testosterone-driven stimulation and 
estradiol- and progesterone-driven inhibition of its abun-
dance. This study also observed mRNA-independent up-
regulation of sat-1 protein expression; while the increase in 
sat-1-Ab-related staining intensity in both liver and kidneys 
of EG-treated females corresponded to higher abundance 
of sat-1 protein, the unchanged expression of mRNA in-
dicated that the observed up-regulation of protein abun-
dance occurred at the posttranscriptional level.
The sat-1 protein via its secretory function may contribute 
to stronger oxaluria and oxalate crystaluria in male than in 
female rats. However, in EG-treated males, a high produc-
tion of oxalate in the liver, and unchanged but high abun-
dance of sat-1 protein in hepatocytes and renal proximal 
tubules may contribute to hyperoxalemia and hyperoxalu-
ria. It is not known whether sat-1 and other oxalate trans-
porters contribute to oxalate secretion along the intestine 
of EG-treated males, and their relative expression and ac-
tivity in control or EG-treated female and male rats has not 
been determined. Hyperoxalemia and hyperoxaluria in EG-
treated males indicate that intestinal secretion of oxalate 
may be low, possibly due to low male-specific expres-
sion of secretory transporters. On the other hand, in the 
presence of elevated expression of hepatic and renal 
sat-1 in EG-treated females, a relatively weak oxalemia and 
absence of hyperoxaluria suggest a possible protective role 
of the sat-1 protein up-regulation. In hepatocytes, the en-
hanced abundance of sat-1 protein is possibly caused by a 
substrate-induced up-regulation in order to eliminate the 
increased production of oxalate from EG, whereas in the 
renal proximal tubules, the function of sat-1 protein could 
be limited by weak oxalemia. Assuming an increased pro-
duction of oxalate from EG in the liver, weak oxalemia and 
absence of oxaluria and oxalate crystaluria indicate some 
compensatory mechanisms that inhibit the crystallization 
of urine oxalate or stimulate oxalate elimination from the 
female body. These mechanisms could include changes in 
concentrations of inhibitors or promotors of calcium-ox-
alate crystallization in the tubule fluid (52,53). Expression 
of one of these inhibitors, osteopontin, in rat kidneys was 
found to be inhibited by testosterone and stimulated by 
estrogens, and these changes strongly affected oxalate 
excretion in control and EG-treated female and male rats 
(61). Additional oxalate secretion could occur in distal in-
testinal segments, possibly via the EG-induced up-regulat-
ed expression of sat-1, CFEX, and other oxalate transport-
ers in the intestinal epithelium. Alternatively, female and 
male rats could have different abundance of oxalate-de-
grading bacteria of Oxalobacter species, which accelerate 
oxalate elimination in EG-treated females. These bacteria 
have been shown to generate a continuous transepithe-
lial gradient for oxalate secretion and ameliorate oxalemia 
and hyperoxaluria in experimental animals and humans 
(3,20,62,63). Finally, due to up-regulated expression of the 
sat-1 in the epithelium, together with abundance of ox-
alate-degrading bacteria in the intestine, EG-treated fe-
male rats could eliminate body oxalate more efficiently, 
leading to lower oxalemia and absence of significant ox-
alate crystaluria.
In conclusion, our finding that the expression of hepatic 
and renal sat-1 protein is stimulated only in EG-treated 
female rats indicates that a weak hyperoxalemia and ab-
sence of hyperoxaluria in these animals may be connected 
with, and thus may explain, lower incidence of hyperoxalu-
ria and oxalate urolithiasis in female experimental animals 
and humans. Our findings and theory suffer from techni-
cal limitations, and thus should be confirmed by function-
al studies. Such studies should reveal whether: a) the liver 
production of oxalate from EG is lower in female than in 
male rats due to lower expression/activity of Hao1, b) the 
elimination of oxalate from hepatocytes via elevated sat-1 
protein expression is increased in EG-treated females, c) 
the intestinal excretion of oxalate is higher in EG-treated 
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females, d) the expression of other oxalate-transporting 
proteins in the liver and kidneys is sex-dependent follow-
ing EG treatment, and e) the intestinal abundance of ox-
alate-degrading bacteria is higher in EG-treated females. 
Our data also indicate that the future studies and possible 
explanation of pathophysiological conditions that cause 
the male-dominant hyperoxaluria and oxalate urolithiasis 
should be shifted from the usual, male-dominant aspects 
(conditions that generate hyperoxalemia, hyperoxaluria, 
and oxalate urolithiasis) to the female-dominant aspects 
(conditions that protect from generation of hyperoxalemia, 
hyperoxaluria, and oxalate urolithiasis).
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